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29 Abstract
30 Introduction: Africa harbours a high burden of pneumococcal disease, with 
31 associated high mortality rates. Despite 34 countries introducing the pneumococcal 
32 conjugate vaccine, which reduces the risk of pneumococcal carriage (a prerequisite 
33 for disease) of some of the most pathogenic pneumococcal serotypes, it remains 
34 uncertain whether they will achieve the sustained direct or indirect protection 
35 necessary to reduce pneumococcal carriage to levels sufficient to interrupt 
36 transmission and disease. We will therefore summarise the available data on the 
37 impact of the pneumococcal conjugate vaccine in reducing vaccine serotype carriage 
38 and pneumococcal pneumonia in Africa between 2000-2019.
39 Methods and analysis: Using a pre-determined search strategy, we will conduct a 
40 comprehensive search of PubMed, MEDLINE database, the Excerpta Medica 
41 Database (EMBASE), the ISI Web of Science (Science Citation Index), Scopus and 
42 the African Index Medicus to identify published studies reporting the prevalence of 
43 Streptococcus pneumoniae carriage (vaccine type and non-vaccine type), incidence 
44 rates of pneumococcal pneumonia and mortality among children, adults and HIV-
45 infected (all-ages) pre- and post-PCV introduction (published between 1st January 
46 2000 and 31st December 2019) in African countries that have introduced 
47 pneumococcal conjugate vaccines (PCV7/10/13) in their routine national 
48 immunisation programs. The studies retained and data extracted will be assessed for 
49 bias using pre-validated tools and checklists. Heterogeneity across studies will be 
50 assessed using the χ2 test on Cochrane Q statistic. A random effect meta-analysis 
51 will be used to estimate the overall prevalence of pneumococcal carriage and 
52 incidence of pneumococcal pneumonia across studies with similar characteristics. 
53 Results will be reported in compliance with the Meta-Analysis Of Observational 
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54 Studies in Epidemiology (MOOSE) guidelines. The protocol has been prepared in 
55 accordance to the 2015 guidelines on Preferred Reporting Items for Systematic 
56 Reviews and Meta-Analyses.
57 Ethics and dissemination: This systematic review will not require ethical approval 
58 as we will be using already published data. The final manuscript will be submitted for 
59 publication in a peer-reviewed journal and presented at conferences. 
60 PROSPERO registration number: CRD42019130976
61
62 Keywords: Streptococcus pneumoniae, Carriage, Pneumococcal conjugate vaccine, 
63 Pneumococcal pneumonia, mortality, Africa
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65
66 Strengths and limitations 
67 • To the best of our knowledge, this study will be the first systematic review that 
68 will comprehensively compare and explore the impact of PCV on carriage, 
69 pneumococcal pneumonia (invasive and non-invasive) and mortality 
70 associated with the disease pre-and post-vaccine introduction in adults and 
71 other at risk groups living in Africa.
72 • Small number of studies eligible across regions could impact the quality of our 
73 estimates.
74 • Presence of high heterogeneity across studies, particularly in countries where 
75 PCV7, PCV10 or PCV13 were in use around the same time and were 
76 serotyping was only done for vaccine-type pneumococcal strains.
77
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80 Introduction
81 Streptococcus pneumoniae (“the pneumococcus”) is a common coloniser of the 
82 nasopharynx and a major cause of morbidity and mortality among children under the 
83 age of 5 years worldwide.1,2 High rates of pneumococcal disease are found in Africa 
84 and other low- and middle-income countries (LMICs), which harbour an 
85 accumulation of factors conducive for high and persistent pneumococcal carriage 
86 and transmission including, high-density living conditions, poverty and high HIV 
87 seroprevalence.3–5 In 2015, pneumococcal pneumonia accounted for 55.4% (95% 
88 Uncertainty Interval (UI): 31.5–79.1) of lower respiratory deaths in all ages.1 
89 Implementation of treatment strategies, which focus on early detection and 
90 antimicrobial therapy of suspected pneumonia cases, has been difficult in Africa.6 
91 Therefore, introduction of an effective vaccine against pneumococcal carriage for 
92 children is crucial in this region as carriage is a prerequisite for disease.
93
94 With support from Gavi (the Vaccine Alliance), 34 African countries introduced the 
95 pneumococcal conjugate vaccines (PCV7/10/13) into their extended immunisation 
96 programmes between 2009 and 2015 7,8 in line with WHO recommendations.9 These 
97 vaccines have been shown to be highly effective in reducing both incidence of 
98 pneumococcal disease and prevalence of carriage by some of the most pathogenic 
99 of the 97 known pneumococcal serotypes.10 Furthermore, the vaccine indirectly 
100 protects the PCV-unvaccinated population against pneumococcal carriage and 
101 disease by reducing pneumococcal transmission from PCV-vaccinated children who 
102 are at greater risk of carriage and, therefore, sources of transmission.2,11–13 
103 However, PCV’s indirect protection on other high-risk populations (including HIV-
104 infected individuals) remains to be seen in Africa.11,14 Studies conducted in Africa 
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105 have demonstrated high nasopharyngeal (NP) carriage of pneumococcus among the 
106 HIV-infected adults on antiretroviral therapy (ART), with estimated point prevalence 
107 ranging between 40-80%.12,15 Therefore, it remains uncertain whether the 
108 introduction of PCV in Africa will achieve the sustained direct or indirect protection 
109 necessary to reduce pneumococcal carriage to levels sufficient to interrupt 
110 transmission and disease.16 
111 Systematic reviews that have been done so far on the impact of PCV in Africa have 
112 focused on carriage and clinical pneumonia endpoints in children.17,18 None have 
113 summarised these data in the adult or important at-risk populations like HIV-infected 
114 individuals. We therefore plan to synthesise the available published data and update 
115 the evidence on the impact of the PCV vaccine introduction on pneumococcal 
116 carriage (VT and NVT), pneumococcal pneumonia and associated mortality in Africa 
117 between 2000–2019. 
118
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120
121 Objectives 
122 General objectives
123 1. To summarise available data on the impact of the pneumococcal conjugate 
124 vaccine on the prevalence of pneumococcal carriage (VT and NVT) and its impact 
125 on pneumococcal pneumonia and associated mortality in Africa between 2000–
126 2019. 
127 Specific objectives
128 Using data published between 2000 and 2019, this review will assess the impact of 
129 PCV by:
130
131 1. Comparing the trend in pneumococcal carriage prevalence in Africa before and 
132 after PCV introduction.
133 2. Comparing the trends in the incidence and/ prevalence of pneumococcal 
134 pneumonia (invasive and non-invasive) in Africa before and after PCV 
135 introduction. 
136 3. Estimating the mortality associated with pneumococcal pneumonia in Africa.
137
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139
140 Methods
141 Information sources, search strategy and study identification
142 We will conduct a comprehensive literature search in PubMed, MEDLINE database, 
143 the Excerpta Medica Database (EMBASE), the ISI Web of Science (Science Citation 
144 Index), Scopus and the African Index Medicus to identify all studies published 
145 between 1st January 2000 to 31st December 2019, meeting our inclusion and 
146 exclusion criteria using the literature search strategy outlined in table 1. Using a 
147 structured screening guide, we will screen the reference lists for eligible articles and 
148 relevant reviews as well as conference abstracts to identify additional sources of 
149 information. Search results will be compiled and managed using the EndNote X9 
150 citation software.
151
152 Eligibility criteria of relevant studies 
153 Inclusion criteria 
154 Population: Children (1-15 years), adults (15-64 years) the elderly (>65yrs), and 
155 HIV-infected individuals (all ages) residing in African countries. 
156 Intervention: Pneumococcal conjugate vaccines (PCV 7, 10, and 13) introduction 
157 into the country’s routine infant immunisation programmes. 
158 Comparators: 10-year period (2000-2010) before PCV introduction versus 10 year-
159 period (2011-2019) after PCV introduction. 
160 Outcomes: Percentage difference in the pooled point prevalence of pneumococcal 
161 carriage post when compared to pre PCV introduction; adjusted prevalence ratios in 
162 the pooled prevalence of pneumococcal pneumonia between post and pre PCV 
163 introduction; and adjusted mortality rate ratios for post and pre PCV introduction.
164
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165 Type of studies: We will include randomised control trials (RCTs), non-randomised 
166 trials and observational studies reporting prevalence of pneumococcal carriage 
167 and/or incidence rates for disease and/or deaths and were published between 1st 
168 January 2000 and 31st December 2019 without language restriction. 
169 Serotyping methods: For pneumococcal carriage, identification and serotyping of 
170 S. pneumoniae must be from a pernasal swab using culture (as per WHO guidelines 
171 19, polymerase chain reaction (Lyt-A gene amplification), microarray or based on 
172 whole genome sequencing (WGS). 
173 Pneumococcal pneumonia: For a pneumococcal pneumonia diagnosis among 
174 adults, a minimum of either (i) symptoms consistent with an acute chest infection (at 
175 least cough or dyspnoea) or (ii) new infiltrates on radiograph and (iii) pneumococcal 
176 antigen detection in either blood, urine or pleural fluid. For children (1-15 years), the 
177 case definition is the criteria for adults plus symptoms of fast breathing, chest-
178 indrawing and nasal flaring. These definitions have been adopted in order to 
179 increase the specificity of identifying pneumococcal pneumonia but are limited in 
180 their sensitivity.  
181
182 Study exclusion criteria
183 1. Any study reporting impact data of vaccines within 12-months of PCV 
184 introduction into routine extended programme of immunisation and data reported 
185 in such a way that impact cannot be defined without data from within 12 months 
186 of PCV introduction.
187 2. Studies with small sample size (less than 50 participants), letters, commentaries, 
188 narratives and editorials, will be excluded as they are likely to have biased 
189 estimates, and this could affect our estimates. 
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190 3. Studies that did not distinguish between pre- and post-PCV introduction periods 
191 in the data presented. 
192
193 Data extraction 
194 Three independent reviewers (NLK, TKN and TDS) will assess the articles for 
195 inclusion based on a pre-determined inclusion and exclusion criteria. Those included 
196 after initial screening will be further evaluated for methodological quality and 
197 presence of bias. Refer to section Appraisal of quality of reporting and the risk of 
198 bias for methods below for further details. Discordance will be resolved by discussion 
199 between reviewers to reach consensus or by a fourth member of the team (KJ). All 
200 articles retrieved will be stored and managed using Endnote X9 throughout the 
201 review process. A standardised data extraction form designed specifically for each 
202 outcome of interest, will be used to collect information on the following parameters: 
203 1. Study identification: name of first author, year of publication, year of participant 
204 inclusion, country, type of publication, language of publication.
205 2. Study characteristics: study design (e.g. cross-sectional, cohort, case control, 
206 clinical trial), setting (hospital, outpatient, population, institution (e.g. school or 
207 care facility), urban/rural), period of surveillance/recruitment, sample size, age 
208 (mean or median; range), proportion of HIV-infected participants and method of 
209 confirmation (if any), proportion on ART (if any), proportion PCV-vaccinated (if 
210 any), proportion with natural pneumococcal carriage (VT, NVT, total), diagnostic 
211 method for pneumococcal carriage detection and serotyping (culture, PCR, DNA 
212 microarray, WGS), diagnostic criteria for pneumococcal pneumonia, duration of 
213 follow up for cohort studies, mortality rates.
214 3. Epidemiological estimates of pneumococcal carriage: prevalence of VT and NVT 
215 carriage 
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216 4. Epidemiological estimates for pneumococcal pneumonia: prevalence and/or 
217 incidence of pneumococcal pneumonia and/or mortality in all subpopulations, 
218 where reported (infants below age of 1 year, children 1-4 years, children 5-15 
219 years and adults (16+ years), the elderly and HIV infected. When estimates are 
220 not available or cannot be computed, the corresponding authors will be 
221 contacted to request for any missing information of these estimates. 
222
223 Appraisal of quality of reporting and the risk of bias
224 We will assess the quality of reporting of the studies using either the Strengthening 
225 the Reporting of Observation studies in Epidemiology (STROBE) or the Consolidated 
226 Standard of Reporting Trials (CONSORT) checklist depending on the nature of the 
227 study (observational study or clinical trial).20–22
228 We will use the 10-item risk of bias tool for prevalence studies developed by Hoy et 
229 al 23 to assess the risk of bias for all the studies included using the full text 
230 publications. Bias risk scores will be presented in a table and inter-rater agreement 
231 will be assessed using a weighted Cohen’s kappa statistic.24–25
232
233 Data analyses and reporting
234 We will use the metaprop command provided within the STATA software v15 to 
235 analyse the data.26 Heterogeneity of studies with similar study characteristics will be 
236 evaluated by the χ2 test on Cochrane’s Q statistic 27 and quantified using I2 values 
237 assuming that I2 of 25%, 50% and 75% represent low, medium and high 
238 heterogeneity respectively.28 Study specific estimates will be pooled through a 
239 random effect meta-analysis to obtain an overall summary estimate of the 
240 prevalence of S. pneumoniae carriage, incidence of pneumococcal pneumonia and 
241 mortality after stabilizing the variance of individual studies using the Free man-Tukey 
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242 double arcsine transformation.29 For impact of PCV on carriage, the percentage 
243 change in point prevalence will be calculated to compare pooled prevalence 
244 estimates in the before and after PCV introduction periods.  Mortality rate ratios will 
245 be calculated to compare pooled mortality rates for the periods before and after PCV 
246 introduction. Meta-analysis results will be presented on a forest plot. Visual analysis 
247 of funnel plot and Egger’s test will be done to detect small study effect.30,31 All tests 
248 will be two-sided and statistical significance will be defined as p<0.05. In case of 
249 marked heterogeneity, a descriptive analysis will be done instead of a meta-analysis. 
250
251 We will report our results according to the Meta-Analysis Of Observational Studies in 
252 Epidemiology (MOOSE) guidelines.32 The process with which studies were selected 
253 will be summarised using a flow diagram. Reasons for study exclusion will be 
254 described and quantitative data will be presented in summary tables and graphs (for 
255 trends) where appropriate. 
256
257 Ethics and dissemination
258 This systematic review will not require ethical approval as we will be using already 
259 published data. The findings will be summarised in a manuscript and submitted in 
260 peer-reviewed journals and presented at relevant conferences. 
261
262 Patient and public involvement
263 This systematic review will use published scientific data and will not involve patients 
264 or members of the public. 
265
266 Contributions: NLK, TKN, KCJ and TDS conceived the study and drafted the 
267 manuscript. The manuscript was revised by DE, SBG, NF, RSH and KCJ. All authors 
268 approved the final version of the manuscript. TKN is the guarantor of the manuscript.
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Table 1 Search strategy 
Search Search terms and combinations
1 (“Pneumococc*” OR “Strep* pneumo” OR “S. pneumo*” OR 
“Streptococc*”)
2 (“Pneumococcal vaccines” OR “streptococcal vaccines” OR 
“Pneumococcal conjugate vaccine”)
3 ((“Africa” OR “Africa*” OR “Algeria” OR “Angola” OR “Benin” OR 
“Botswana” OR “Burkina Faso” OR “Burundi” OR “Cape Verde” OR 
“Cameroon” OR “Central African Republic” OR “Chad” OR “Comoros” 
OR “Democratic Republic of Congo” OR “Congo” OR “Ivory Coast” OR 
“Djibouti” OR “Egypt” OR “Equatorial Guinea” OR “Eritrea” OR 
“Ethiopia” OR “Gabon” OR “Gambia” OR “Ghana” OR “Guinea” OR 
“Guinea-Bissau” OR “Kenya” OR “Lesotho” OR “Liberia” OR “Libya” OR 
“Madagascar” OR “Malawi” OR “Mali” OR “Mauritania” OR “Mauritius” 
OR “Morocco” OR “Mozambique” OR “Namibia” OR “Niger” OR 
“Nigeria” OR “Rwanda” OR “Sao Tome and Principe” OR “Senegal” OR 
“Seychelles” OR “Sierra Leone” OR “Somalia” OR “South Africa” OR 
“South Sudan” OR “Sudan” OR “Swaziland” OR “Tanzania” OR “Togo” 
OR “Tunisia” OR “Uganda” OR “Zambia” OR “Zimbabwe”) NOT (“pig*” 
OR “Papua”))
4 (“carriage” OR “Carriage” OR “coloniz*” OR “Coloniz*” OR “colonis*” OR 
“Colonis*” OR “acquisition” OR “acquir*” OR “carrier state” OR “Carrier 
state”) 
5 (“Pneumococc* pneumonia” OR “Community acquired pneumonia” OR 
“Non-invasive pneumonia” OR “Invasive pneumococc* pneumonia” OR 
“CAP” OR “IPD”)
6 (“mortality rate” OR “case fatality” OR “death rate”)
7 Carriage: 
#1 AND #2 AND #3 AND #4 
8 Pneumococcal pneumonia and associated mortality:
#1 AND #2 AND #3 AND (#5 AND/OR #6)
9 Filters: Publication date from 2000/01/01 to 2019/06/30; Humans
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PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item 
No 
Checklist item                                                          Page  
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review 1 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such n/a 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 3 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of 
corresponding author 
1 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 12 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; 
otherwise, state plan for documenting important protocol amendments 
n/a 
Support:    
 Sources 5a Indicate sources of financial or other support for the review 12 
 Sponsor 5b Provide name for the review funder and/or sponsor n/a 
 Role of 
sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol n/a 
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known 5-6 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, 
comparators, and outcomes (PICO) 
7 
METHODS  
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years 
considered, language, publication status) to be used as criteria for eligibility for the review 
8-9 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other 
grey literature sources) with planned dates of coverage 
8 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be 16 
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repeated 
Study records:    
 Data 
management 
11a Describe the mechanism(s) that will be used to manage records and data throughout the review 9-11 
 Selection 
process 
11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review 
(that is, screening, eligibility and inclusion in meta-analysis) 
9 
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any 
processes for obtaining and confirming data from investigators 
9-10 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data 
assumptions and simplifications 
10 
Outcomes and 
prioritization 
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with 
rationale 
10-11 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information will be used in data synthesis 
10-11 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 11 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and 
methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ) 
11 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 11 
15d If quantitative synthesis is not appropriate, describe the type of summary planned 11 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 11 
Confidence in 
cumulative 
evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 11 
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.  
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647. 
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